Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company’s global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), […]
QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia
January 29, 2026 10:46 ET | Source: Quetzal Therapeutics CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, the company’s investigational oral arsenic trioxide capsule, for the treatment of patients with acute promyelocytic leukemia (APL). […]
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial of QTX-2101, an investigational oral arsenic trioxide capsule. The trial will evaluate the efficacy, safety, and pharmacokinetics of QTX-2101, as a potential […]
Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer
September 16, 2025 12:10 ET | Source: Quetzal Therapeutics CHICAGO, Sept. 16, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company focused on developing transformative therapies for patients with rare and life-threatening diseases, today announced the appointment of Dr. Shaad Abedin as Chief Medical Officer. Dr. Abedin brings to Quetzal extensive experience in oncology drug development, translational […]
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.